TREACE MEDICAL CONCEPTS, INC.(TMCI)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

TREACE MEDICAL CONCEPTS, INC. (TMCI) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores TMCI at 25.6/100 on a 32-signal composite quality model, placing it at rank #2,659 of 2,962 stocks — the bottom half of the AI-ranked universe. Areas of concern include institutional flow (7.2) and balance sheet strength (7.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 11.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), TREACE MEDICAL CONCEPTS, INC. reports quarterly revenue of $45.4M, net income of $-15.9M, an operating margin of -33.0%. Top institutional holders of TMCI by reported 13-F value include ARMISTICE CAPITAL, BANK OF AMERICA, GAGNON SECURITIES, based on the most recent SEC filings. TMCI trades on the Nasdaq exchange and files with the SEC under CIK 1630627. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TMCI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for TREACE MEDICAL CONCEPTS, INC. directly from SEC EDGAR.